Patents by Inventor Justin R. Fallon
Justin R. Fallon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230304012Abstract: Methods and compositions for increasing muscle regeneration and for preventing or treating diseases, disorders or conditions associated with neuromuscular dysfunction, are provided herein.Type: ApplicationFiled: October 16, 2020Publication date: September 28, 2023Inventors: Justin R. FALLON, Laura A. MADIGAN, Ashley E. WEBB, Beth MCKECHNIE, Lauren FISH, Diego JAIME, John PAGE
-
Publication number: 20220193114Abstract: Methods and compositions for increasing neurogenesis and for preventing or treating diseases, disorders or conditions associated with neurodegeneration, are provided herein.Type: ApplicationFiled: April 17, 2020Publication date: June 23, 2022Inventors: Justin R. FALLON, Ashley E. WEBB, Beth McKECHNIE, Tali SORETS, Lauren FISH, Diego JAIME, John PAGE
-
Publication number: 20180327469Abstract: The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: ApplicationFiled: May 10, 2018Publication date: November 15, 2018Inventors: Justin R. Fallon, Alison R. Amenta, Beth A. McKechnie, Michelle Dechene, Atilgan Yilmaz
-
Patent number: 9969785Abstract: The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: May 17, 2011Date of Patent: May 15, 2018Assignee: Brown UniversityInventors: Justin R. Fallon, Alison R. Amenta, Beth A. McKechnie, Michelle Dechene, Atilgan Yilmaz
-
Patent number: 9958458Abstract: The present disclosure provides methods for predicting a patient's response to biglycan therapy for diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of such diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. This application also provides combination therapeutics, such as a biglycan therapeutic and a utrophin therapeutic.Type: GrantFiled: December 27, 2011Date of Patent: May 1, 2018Assignee: Brown UniversityInventors: Alison R. Amenta, Atilgan Yilmaz, Beth A. McKechnie, Justin R. Fallon
-
Publication number: 20150182589Abstract: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.Type: ApplicationFiled: August 29, 2014Publication date: July 2, 2015Inventors: Justin R. Fallon, Michael Rafii, Mark A. Bowe, Beth A. McKechnie, Alison R. Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 8822418Abstract: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.Type: GrantFiled: May 24, 2010Date of Patent: September 2, 2014Assignee: Brown UniversityInventors: Justin R. Fallon, Michael Rafii, Mark A. Bowe, Beth McKechnie, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 8691766Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: February 8, 2012Date of Patent: April 8, 2014Assignee: Brown University Research FoundationInventors: Justin R. Fallon, Beth A. McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison R. Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 8658596Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: September 14, 2010Date of Patent: February 25, 2014Assignee: Brown University Research FoundationInventors: Justin R. Fallon, Mark A. Bowe, Beth McKechnie, Michael Rafii, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Publication number: 20140038906Abstract: The present disclosure provides methods for predicting a patient's response to biglycan therapy for diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of such diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. This application also provides combination therapeutics, such as a biglycan therapeutic and a utrophin therapeutic.Type: ApplicationFiled: December 27, 2011Publication date: February 6, 2014Applicant: BROWN UNIVERSITYInventors: Alison R. Amenta, Atilgan Yilmaz, Beth A. McKechnie, Justin R. Fallon
-
Publication number: 20120245095Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: ApplicationFiled: February 8, 2012Publication date: September 27, 2012Applicant: Brown University Research FoundationInventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 8138154Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: July 6, 2009Date of Patent: March 20, 2012Assignee: Brown University Research FoundationInventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Publication number: 20120004178Abstract: The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: ApplicationFiled: May 17, 2011Publication date: January 5, 2012Inventors: Justin R. Fallon, Alison R. Amenta, Beth A. McKechnie, Michelle Dechene, Atilgan Yilmaz
-
Publication number: 20110183910Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: ApplicationFiled: September 14, 2010Publication date: July 28, 2011Applicant: Brown University Research FoundationInventors: Justin R. Fallon, Mark A. Bowe, Beth McKechnie, Michael Rafii, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Publication number: 20110053854Abstract: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.Type: ApplicationFiled: May 24, 2010Publication date: March 3, 2011Inventors: Justin R. Fallon, Michael Rafii, Mark A. Bowe, Beth McKechnie, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 7816322Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: February 22, 2008Date of Patent: October 19, 2010Assignee: Brown University Research FoundationInventors: Justin R. Fallon, Mark A. Bowe, Beth McKechnie, Michael Rafii, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 7759314Abstract: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.Type: GrantFiled: August 15, 2002Date of Patent: July 20, 2010Assignee: Brown UniversityInventors: Justin R. Fallon, Michael Rafii, Alison Amenta, Mark Bowe, Beth McKechnie, Mary Lynn Mercado, Hiroki Hagiwara
-
Publication number: 20100130405Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: ApplicationFiled: July 6, 2009Publication date: May 27, 2010Applicant: Brown Technology PartnershipsInventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Raymond Ferri, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 7612038Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: February 20, 2002Date of Patent: November 3, 2009Assignee: Brown UniversityInventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Publication number: 20080274966Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: ApplicationFiled: February 22, 2008Publication date: November 6, 2008Applicant: Brown University Research FoundationInventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Raymond Ferri